Clifford Samuel

Part of Medtronic Plc, Nellcor Puritan Bennett, Inc. is a company that manufactures and supplies respiratory care products. The company is based in Pleasanton, CA. Nellcor Puritan Bennett was acquired by Mallinckrodt, Inc.(Old) on August 26, 1997 for $1,805.05 million.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA.

Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA.

Calibra Medical LLC develops and markets medical devices and technologies in the diabetes sector. Its products include finesse and insulin delivery devices. The company was founded by Daniel Hawkins and Clifton A. Alferness in 2004 and is headquartered in Wayne, PA.

ReVision Optics, Inc. develops optical solutions for the treatment of presbyopia. The company also develops Raindrop Near Vision Corneal Inlay, which is a refractive surgery solution. ReVision Optics was founded by Hansen A. Yuan, Adrian Koppes and Alok Nigam in 1996 and is headquartered Lake Forest, CA.

Transcend Medical, Inc. operates as a medical device company. It develops medical devices for the treatment of glaucoma, the cause of adult irreversible blindness. The company was founded in 2005 and is headquartered in Lake Forest, CA.

Labrys Biologics, Inc. provides biotechnology services. It is a venture-financed development stage biotechnology company, which focuses on treatments for chronic migraine. The company was founded by Corey S. Goodman in 2012 and is headquartered in San Francisco, CA.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

GenPharm International, Inc. manufactures biopharmaceutical products. The company works towards the application of transgenic animal technology to the development of human antibody products, which are used for therapeutic uses. It was founded in 1988 and is located in San Jose, CA.

Bain & Co., Inc. provides management consulting services. It offers advisory services to the companies on their critical issues and opportunities: strategy, marketing, organization, operations, technology and mergers and acquisitions, across all industries and geographies. The company was founded in 1973 and is headquartered in Boston, MA.

Trinity Biosystems, Inc. develops and formulates orally delivered bio-therapeutic macromolecules. It offers TriPex system, an approach to macromolecule delivery that works cooperatively with the natural physiology of the body. The system utilizes a specific and natural biological transport mechanism: a receptor-mediated transcellular transport pathway that allows passage through the mucosal epithelium and delivery of the therapeutic payload into the blood. The company was founded by Randall J. Mrsny on July 19, 2002 and is headquartered in Menlo Park, CA.

Minimally Invasive Devices, Inc. develops laparoscopic visualization tools and systems. It offers FloShield Air, a vortex barrier technology that provides a continuous flow of dry carbon dioxide gas over the tip of the scope, instantly defogging it while continuously shielding it from condensation, debris, and smoke. It also offers FloShield Plus, an intra-operative flush that can be used to clean a scope if it gets dirty during surgery. The company was founded by Wayne L. Poll and Jodi Wolfe in 2006 and is headquartered in Columbus, OH.

Part of Sanofi, Genzyme Molecular Oncology is a company that develops novel cancer therapeutics and diagnostics. The company is based in Cambridge, MA. The company was founded by Gail J. Maderis.

Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California.

ALUS Liquidation Corp. develops, manufactures, and sells medical products. The company is based in Irvine, CA.

Glooko, Inc. provides mobile diabetes management solution for patients, health systems, and payer groups. It enhances the way diabetics and care providers interact by leveraging the power of mobile, cloud, and analytics to transform diabetes management. The company was founded by Yogen K. Dalal, Chamath Palipitiya, Sundeep Madra, and Anita Matthew in June 2010 and is headquartered in Mountain View, CA.

OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA.

ChromaCode, Inc. develops software and manufactures laboratory instruments. It uses digital signal processing to improve clinical molecular analysis. The company was founded by Aditya Rajagopal, Alexander G. Dickinson, Axel Scherer, and Gregory J. Gosch in 2012 and is headquartered in Carlsbad, CA.

Hyalex Orthopaedics, Inc. manufactures medical devices. The firm focus on developing and commercializing new products that feature HYALEX materials technology, a synthetic polymer that mimics cartilage. Its synthetic HYALEX material has the capability of maintaining low friction and low wear under the high loads encountered in human joints. The company is headquartered in Lexington, MA.

Valitor, Inc. develops a new generation of biotechnology drugs. It develops methods of modifying therapeutic proteins to achieve substantial control over pharmacokinetics, target specificity and bioactivity. The company was founded by Kevin E. Healy, Wesley M. Jackson and David Schaffer in 2010 and is headquartered in Berkeley, CA.

Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York.

Qlaris Bio, Inc. operates as a biotechnology company. The company was founded by Thurein Htoo and Barbara Wirostko and is headquartered in Wellesley, MA.

Soteria Biotherapeutics, Inc. develops next-generation immunotherapies. Its development allows to control the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.The company was founded by Zachary Hill and Alexander Martinko and is headquartered in San Francisco, CA.

MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts.

54Gene, Inc. is an American health technology company that focuses on advancing the field of genomics to improve diagnostic and treatment outcomes for diverse populations. 54Gene is a research, services, and development company located in Nigeria and the United States. The company generates genetic insights from research cohorts in diverse populations to improve the development, availability, and efficacy of therapeutics and diagnostics. The company was founded in 2019 by Dr. Abasi Ene-Obong to improve our understanding of the world's most genetically diverse population. Ron Chiarello has been the CEO of the company since 2023.

Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market.